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Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14
days of concomitant therapy. Foscarnet clearance in plasma averaged (+ standard deviation) 0.16 ± 0.03 and
0.13 ± 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not
significantly altered, with a mean (± standard deviation) oral clearance of 2.7 ± 1.0 and 2.6 ± 0.8 liter/h/kg
for the 2 study days, respectively.
Foscamet (trisodium phosphonoformate; Foscavir) is a
pyrophosphate analog with antiviral activity in vitro against
a variety of RNA and DNA viruses. It is commonly used for
the treatment of cytomegalovirus disease in immunocompro-
mised patients, such as those with AIDS or those undergoing
organ transplantation. Patients with infection due to the
human immunodeficiency virus (HIV) are often treated with
this agent for cytomegalovirus retinitis (9). In addition,
foscarnet is active against HIV both in vitro and in vivo (10,
15). It has also been used concurrently with the nucleoside
analog zidovudine (ZDV) in the management of patients with
AIDS. Studies have shown that foscarnet and ZDV when
administered together additively or synergistically inhibit
HIV replication in vitro (4, 13). Furthermore, the clinical use
of these two drugs together has recently been reported to
result in an additive in vivo anti-HIV effect as measured by
p24 antigen (12).
The pharmacokinetic disposition of both foscarnet and
ZDV has been well described (1-3, 16, 17, 19). Foscarnet is
a highly polar acidic compound that is primarily excreted
unchanged in urine by both filtration and secretion. ZDV is
mostly metabolized by the liver to an inactive glucuronide
metabolite (GZDV), which is subsequently renally excreted.
Additionally, 20% of ZDV is excreted unchanged in the
urine, and its renal clearance as well as that for GZDV has
been shown to be decreased in the presence of probenecid
(20). A potential interaction may therefore exist between
these two drugs. Presently, there is no information available
regarding the pharmacokinetic disposition of these two drugs
when administered concomitantly. Substantial changes in
the kinetics of either of these drugs could lead to unexpected
toxicity. Therefore, the objectives of this study were to
determine the distribution and elimination patterns of fos-
carnet and ZDV when administered alone and in combina-
tion to AIDS patients.
This study is part of an AIDS Clinical Trials Group study
(053) evaluating the tolerance and antiviral effect of intermit-
tent foscarnet therapy for HIV infection in patients receiving
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long-term ZDV therapy (12). Enrollment in this open phase
I study included stable AIDS or AIDS-related-complex
patients who had already received ZDV for 8 to 16 weeks.
Enrollment procedures have been detailed previously (12).
Briefly, patients with moderate-to-severe renal impairment
(serum creatinine concentration, >2 mg/dl) were excluded
from the study. In addition, patients receiving antimetabolic,
immunomodulatory, nephrotoxic, or other antiviral therapy
were also excluded. In addition to the required laboratory
tests for the study, HIV p24 antigen tests of sera were
carried out before and after study completion.
Following 4 weeks of prestudy monitoring during which
ZDV alone was administered on an outpatient basis, all
subjects were administered foscarnet and ZDV concomi-
tantly for a 14-day study period. The subjects were hospi-
talized, during which time they received foscarnet at a
dosage of approximately 30 mg/kg of body weight every 8 h
intravenously and ZDV at a dosage of 200 mg every 4 h
orally. Foscarnet solution (24 mg/ml) was administered
undiluted via a central venous catheter or diluted to 8 to 12
mg/ml in normal saline or 5% dextrose via a peripheral
intravenous catheter over a 1-h period. Foscarnet doses
were reduced in subjects with mild renal impairment (11).
Subsequent to the 14-day study period, subjects resumed
ZDV treatment alone.
For pharmacokinetic evaluation of ZDV alone, subjects
were administered 200 mg of ZDV on day -1 of the study
period. Blood samples were collected for the determination
of ZDV concentrations in plasma as described below. ZDV
was then held for 2 days (days -1 to 1) so that foscarnet
could be studied in the absence of detectable ZDV levels in
plasma. The first dose of foscarnet was administered on day
0 and was continued every 8 h from day 0 to day 14. Each
dose of foscarnet averaged 30 mg/kg and was infused over 1
h. (See Table 1 for dosing specifications.) On day 1, a
foscarnet steady-state pharmacokinetic profile was deter-
mined for the 8 h following the fourth dose of foscarnet.
Time to steady state was based on a functional half-life
ranging from 3 to 4.5 h. Blood samples (4 ml each) were
collected prior to the fourth dose and at 1, 1.25, 1.5, 2, 3, 4,
6, and 8 h. After this 8-h period, ZDV therapy was reinsti-
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TABLE 1. Subject demographics
Serum creatinine concn (mg/dl) Foscarnet dose (mg)
Subject no. Age (yr) Wt (kg)
Day 1 Day 14 Day 1 Day 14
1 54 61 0.9 1.7 1,494 832
2 26 61 0.9 0.8 1,866 1,866
3 33 86 0.9 1.0 2,571 2,622
4 26 86 0.8 0.8 2,592 2,592
5 40 65 0.9 0.9 1,840 1,840
Mean (SD) 36 (13) 72 (14) 0.9 (0.1) 1.0 (0.4) 2,073 (542) 1,950 (840)
tuted, along with the fifth dose of foscamet, and continued at
a dosage of 200 mg every 4 h. An additional foscarnet
pharmacokinetic profile was carried out on day 14 (after 14
days of concomitant ZDV therapy). Blood samples were
collected prior to and following the last time of concomitant
administration as described above and at 12, 18, and 24 h for
the determination of foscarnet concentrations in plasma.
To study the pharmacokinetic disposition of ZDV and
GZDV, blood samples were collected on day -1 (in the
absence of foscarnet), day 1 (during the fifth dose of foscar-
net administration), and on day 14 (during the last dose of
foscarnet). Blood samples (4 ml) were collected prior to
ZDV administration on day -1 and at 0.5, 0.75, 1, 1.25, 1.5,
2, 2.5, 3, 4, and 6 h. On day 1, foscarnet (fifth dose) and ZDV
were administered together, and blood samples were col-
lected as on day -1. Blood samples were also collected prior
to and following the last dosing of concomitant administra-
tion as above and at 8 and 12 h for the determination of ZDV
and GZDV concentrations in plasma.
Each sample for foscarnet and ZDV concentration mea-
surement was collected in heparinized Vacutainer tubes,
placed immediately on ice, and centrifuged. Plasma was
harvested, stored in glass dram vials, and frozen at -20°C to
await further processing.
All foscarnet plasma samples were analyzed by a high-
performance liquid chromatographic (HPLC) method with
electrochemical detection (8, 14). Prior to analysis, all sam-
ples were heat deactivated for 45 min at 56°C to ensure
inactivation of HIV. Studies have shown that foscamet is
stable during heat deactivation. The lower limit of detection
for this assay is 33 ,uM in plasma, and the interday and
intraday coefficients of variation ranged from 2.4 to 4.0% and
1.0 to 1.8% respectively.
Quantitations of ZDV and GZDV were carried out with an
HPLC assay developed by Good et al. (7). Samples were
processed, frozen, and heat deactivated for 45 min at 56°C as
described above. The lower limits of detection of ZDV and
GZDV were 0.10 and 0.21 ,uM, respectively, for plasma,
with an interday and intraday coefficient of variation range
from 3.4 to 5.7% and 0.6 to 5.4% for ZDV and 3.2 to 14.8%
and 0.6 to 9.0% for GZDV.
Noncompartmental pharmacokinetic analysis was used to
determine the pharmacokinetic parameters of foscarnet and
ZDV (6). The area under the concentration in plasma-time
curve (AUC) was calculated by using the linear trapezoidal
rule to the peak concentration and the log trapezoidal rule
for the descending portion of the curve. Extrapolation to
infinity was obtained by taking the last observed concentra-
tion divided by lambda z, which was derived from a fit of the
AUC determined by nonlinear regression with a two-com-
partment model with lly' weighting by utilizing the program
RSTRIP (Micromath). The half-life was calculated by divid-
ing 0.693 by lambda z.
Estimates of plasma clearance (CL) were calculated by
using the equation CL = dose/AUC. The apparent volume of
distribution (Vp) was calculated by using the equation V, =
CL/lambda z. For ZDV, when the drug was given orally,
these parameters become CL/F (F, bioavailability factor)
and V1/F. From the graphical analysis of the data, peak
concentration and time to peak were determined.
Statistical significance was determined by using the non-
parametric correlate of the paired-t test, the Wilcoxon signed
rank test. A P value of less than 0.05 was considered
significant. All values were reported as the means + stan-
dard deviations.
Five of six male patients enrolled in the clinical portion of
this study (three with AIDS-related complex and two with
AIDS) had pharmacokinetic evaluations carried out. Their
mean (± standard deviation) age was 35 ± 13 years and their
mean weight was 73 ± 14 kg. Estimated renal function was
normal in all patients on day 1 (mean creatinine concentra-
tion in serum: 0.88 ± 0.05 mg/dl) and day 14 (0.84 ± 0.05
mg/dl), except for subject 1, who developed a rise in serum
creatinine from 0.9 to 1.7 during the 14 days of the study.
Demographics for the subjects are summarized in Table 1.
Steady-state peak concentrations achieved immediately fol-
lowing the 1-h infusion averaged 264 ± 66 ,umol on day 1 and
246 ± 125 pmol on day 14 following 14 days of concomitant
ZDV therapy. These levels in plasma declined in a biexpo-
nential fashion, with concentrations at 8 h being undetect-
able in most cases.
Pharmacokinetic parameters for foscarnet are summarized
in Table 2. The clearance of foscamet averaged 0.16 ± 0.03
liter/h/kg on day 1 of the study (in the absence of ZDV) and
0.13 ± 0.05 liter/h/kg on day 14 (following ZDV-foscarnet
therapy). This difference was not significant (P = 0.14). The
change in clearance differed by 19% on day 14. When
changing renal function was eliminated as a factor (subject
1), this change averaged only 13% and was also not signifi-
cant (P = 0.27). The volume of distribution (V,3) and half-life
(t1/2) of foscarnet did not differ significantly on the 2 study
days.
Figure 1 illustrates little alteration in the foscarnet con-
centration in plasma time profile in the absence and presence
of ZDV for subject 2.
As a measure of efficacy, the percentage decrease in HIV
p24 antigen concentrations in serum determined during the
14-day study period (12) correlated with day-14 foscarnet
steady-state AUC, with a coefficient of determination (r2) of
0.62. When combined with similar pharmacodynamic data
previously published (10), this correlation was significant,
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TABLE 2. Foscarnet pharmacokinetic parameters
ZDV dose and CL
t2 h 3(ltrk)CnpekAUGsubject no. (liter/h/kg) (h) V (liter/kg) ConcnPak (moliter)
Without ZDV'
1 0.13 2.2 0.41 266 638
2 0.16 1.3 0.32 285 618
3 0.15 1.4 0.32 305 640
4 0.20 2.7 0.76 151 505
5 0.16 2.6 0.58 313 634
Mean (SD) 0.16 (0.03) 2.0 (0.6) 0.48 (0.19) 264 (66) 607 (58)
With ZDV
1 0.05 8.0 0.58 97 895
2 0.16 6.2 1.44 333 626
3 0.13 4.5 0.83 395 784
4 0.12 2.2 0.38 143 774
5 0.17 2.1 0.52 262 585
Mean (SD) 0.13 (0.05) 4.6 (2.6) 0.75 (0.42) 246 (125) 733 (126)
P 0.14 0.22 0.35 0.69 0.14
a Control.
with a coefficient of determination (r2) of 0.55 (P = 0.02)
(Fig. 2).
Pharmacokinetic data for ZDV are presented in Table 3.
Peak ZDV concentrations averaged 3.0 ± 0.7 and 3.1 ± 1.4
,umol for day -1 (no foscarnet) and day 14, respectively.
ZDV oral clearance averaged 2.7 ± 1.0 liter/h/kg and 2.6 +
0.8 liter/h/kg for the 2 study days. Figure 3 illustrates the
AUC for ZDV in the presence and absence of foscarnet for
subject 4. All changes in parameters, including V,3 and t1/2,
were not significantly different. The ratio of the AUC for the
glucuronide metabolite of ZDV (GZDV) to the AUC for









averaging 4.1 + 1.0 and 5.0 + 1.1 for the 2 study days,
respectively (P = 0.27).
The antiretroviral effect of combination foscarnet-ZDV
therapy has previously been shown to be additive for the
patients enrolled in this study (12), as indicated by a signif-
icant decline in HIV p24 antigen concentrations in serum. In
addition, in vitro studies have suggested that these two drugs
may act synergistically against HIV (4, 13).
A possible explanation for the additive or synergistic
anti-retroviral effects of these two drugs may be that they are
due to alteration in their pharmacokinetic behavior. Foscar-
net is eliminated principally by the renal route, with 83% of
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FIG. 2. Correlation comparing percentage decrease in HIV p24 antigen concentrations in serum and the AUC for foscarnet on day 14
(n = 9), including data for four subjects previously published (12). Coefficient of determination (r2) = 0.55 (P = 0.02).
the unchanged drug recovered in urine (1, 17, 18) while only
20% of ZDV is excreted unchanged and 80% is excreted as a
glucuronide metabolite. Though a potential interaction may
exist between these two compounds, no significant alteration
in the disposition of either drug was found in this limited
pharmacokinetic study. On the basis of the study results, a
power analysis was carried out, resulting in a power of only
0.45 to detect a difference in mean clearance of 30% for these
TABLE 3. ZDV pharmacokinetic parameters
Foscarnet dose and CL/F t (h) V/F Concnpeak t (h)subject no. (liter/h/kg) n (liter/kg) (Cmol)nc
Without foscarnetz
1 3.2 3.2 14.8 2.1 1.5
2 3.7 2.1 11.3 3.3 1.5
3 1.9 1.3 3.4 2.3 1.3
4 1.5 1.1 2.4 3.7 0.6
5 3.2 1.3 6.2 3.0 0.8
Mean (SD) 2.7 (1.0) 1.8 (0.9) 7.6 (5.3) 3.0 (0.7) 1.1 (0.4)
With foscarnet (5th dose)
2 2.8 1.2 4.9 5.7 0.5
3 2.0 2.2 6.4 2.3 1.3
With foscarnet (last dose)
1 1.7 1.3 3.1 4.6 1.0
2 3.3 1.6 7.6 2.5 1.0
3 2.3 1.4 4.7 4.6 0.5
4 2.1 1.4 4.2 1.8 1.5
5 3.5 1.1 5.6 2.1 1.0
Mean (SD) 2.6 (0.8) 1.4 (0.2) 5.0 (1.7) 3.1 (1.4) 1.0 (0.4)
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FIG. 3. ZDV AUC for subject 4 in the absence and presence of foscarnet.
five individuals studied under two different conditions.
Therefore, the inability of this study to demonstrate a
significant interaction does not entirely exclude this possi-
bility.
On the basis of the results obtained, little alteration in
foscarnet disposition was detected. Peak concentrations in
plasma following the 1-h infusion were similar and averaged
approximately 250 ,umol both in the absence and presence of
ZDV. The foscarnet clearance in plasma for these patients
was also similar before and after concomitant therapy (0.16
and 0.13 liter/h/kg) and was comparable to the mean value of
0.11 liter/h/kg reported previously by our group (1). The
apparent volume of distribution also was not altered by
concomitant ZDV administration and was consistent with
earlier findings that ranged from 0.52 to 0.74 liter/kg (1, 17,
18).
In two of the five subjects, the plasma clearance of
foscamet declined substantially following 14 days of com-
bined therapy, which for subject 1 was attributed to a
proportional decline in renal function. For subject 4, reasons
for a decline in clearance were uncertain.
ZDV parameters were not altered significantly in the
presence of foscarnet. Mean peak concentrations in plasma
averaged 3.0 ,umol following an oral 200-mg dose without
and during foscarnet administration; this result is also con-
sistent with previously published findings (3, 16, 19). The
oral clearance in this study ranged from 2.6 to 2.7 liter/h/kg
in the absence and presence of foscarnet and was in close
agreement with values ranging from 2.2 to 2.7 liter/h/kg
observed by other investigators (16, 19). The ZDV half-life
has previously been reported to be approximately 1 h (3, 16,
19) compared with a range of 1.4 to 1.8 h with and without
foscarnet therapy in these patients. Considerable interpa-
tient variability has been observed with this parameter for
reasons that remain unclear.
As recently published, HIV p24 antigen levels in serum
declined significantly over 14 days of combined foscarnet-
ZDV therapy, with decreases ranging from 26 to 75% despite
chronic ZDV therapy prior to study entry (12). These
changes were therefore attributed to the addition of foscar-
net and may be explained by a difference in the mechanism
of antiviral effect between these two drugs. Interestingly, a
foscarnet dose-response effect was suggested by the corre-
lation between the decline in p24 antigen levels in serum and
the steady-state foscarnet AUC for these subjects and for
data previously published by our group (r2 = 0.55) (10). A
similar correlation between these two measurements has
been presented elsewhere, with a coefficient of determina-
tion (r2) of 0.58 (5). These results imply that the maintenance
of adequate foscarnet levels and the extent of foscarnet
exposure may be important in its antiretroviral effect.
In summary, this study of five patients was unable to
demonstrate a significant pharmacokinetic interaction be-
tween these two drugs, especially in view of the slight
changes in renal function attributed to foscarnet.
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